ArticleContemporary oncology (Poznan, Poland)2025
The activity of pyrazoline B compound in inhibiting proliferation of breast cancer cells with human epidermal growth factor receptor 2 overexpression.
Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In silico approach andContemporary oncology (Poznan, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the cytotoxicity and elucidate the mechanism of action of the chemical compound pyrazoline B in inhibiting the proliferation of MCF 7/HER-2 breast cancer cells. Material and methods: Pyrazoline B was synthesized at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada. Cytotoxic activity against MCF 7/HER-2 cells was assessed using the MTT assay. Flow cytometry was used to analyse cell cycle arrest (G2/M phase), induction of apoptosis and necrosis, and the expression of PI3K, mTOR, and reactive oxygen species (ROS). Results: Pyrazoline B exhibited cytotoxicity with an IC Conclusions: Pyrazoline B inhibited cell cycle progression, induced apoptosis and necrosis, downregulated PI3K/mTOR signalling, and elevated ROS levels in MCF 7/HER-2 cells compared with the untreated control cells. These findings suggest that pyrazoline B is a promising candidate for development as a novel anticancer agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.